

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Microalbuminuria and cardiorenal risk: old and... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1659/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1659" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Microalbuminuria and cardiorenal risk: old and new evidence in different populations" />
    
            <meta name="og:title" content="F1000Research Article: Microalbuminuria and cardiorenal risk: old and new evidence in different populations.">
            <meta name="og:description" content="Read the latest article version by Diego Francisco M&aacute;rquez, Gema Ruiz-Hurtado, Julian Segura, Luis Ruilope, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="18821">
            <meta name="article-id" content="17212">
            <meta name="dc.title" content="Microalbuminuria and cardiorenal risk: old and new evidence in different populations">
            <meta name="dc.description" content="Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes.">
            <meta name="dc.subject" content="albuminuria, cardiovascular risk, chronic kidney disease">
            <meta name="dc.creator" content="M&aacute;rquez, Diego Francisco">
            <meta name="dc.creator" content="Ruiz-Hurtado, Gema">
            <meta name="dc.creator" content="Segura, Julian">
            <meta name="dc.creator" content="Ruilope, Luis">
            <meta name="dc.date" content="2019/09/19">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.17212.1">
            <meta name="dc.source" content="F1000Research 2019 8:1659">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="albuminuria">
            <meta name="prism.keyword" content="cardiovascular risk">
            <meta name="prism.keyword" content="chronic kidney disease">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/09/19">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1659">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.17212.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1659">
            <meta name="citation_title" content="Microalbuminuria and cardiorenal risk: old and new evidence in different populations">
            <meta name="citation_abstract" content="Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes.">
            <meta name="citation_description" content="Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes.">
            <meta name="citation_keywords" content="albuminuria, cardiovascular risk, chronic kidney disease">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Diego Francisco M&aacute;rquez">
            <meta name="citation_author_institution" content="Unidad de Hipertensi&oacute;n Arterial-Servicio de Cl&iacute;nica M&eacute;dica, Hospital San Bernardo, Salta, Argentina">
            <meta name="citation_author" content="Gema Ruiz-Hurtado">
            <meta name="citation_author_institution" content="Instituto de Investigaci&oacute;n Imas12 and Unidad de Hipertensi&oacute;n, Hospital 12 de Octubre, Madrid, Spain">
            <meta name="citation_author" content="Julian Segura">
            <meta name="citation_author_institution" content="Instituto de Investigaci&oacute;n Imas12 and Unidad de Hipertensi&oacute;n, Hospital 12 de Octubre, Madrid, Spain">
            <meta name="citation_author" content="Luis Ruilope">
            <meta name="citation_author_institution" content="Departamento de Medicina Preventiva y Salud P&uacute;blica, Universidad Aut&oacute;noma, Madrid, Spain">
            <meta name="citation_author_institution" content="Instituto de Investigaci&oacute;n Imas12 and Unidad de Hipertensi&oacute;n, Hospital 12 de Octubre, Madrid, Spain">
            <meta name="citation_author_institution" content="Escuela de Estudios Postdoctorales and Investigaci&oacute;n, Universidad de Europa de Madrid, Madrid, Spain">
            <meta name="citation_publication_date" content="2019/09/19">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1659">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.17212.1">
            <meta name="citation_firstpage" content="1659">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1659/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1659.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=18821 /> <input type=hidden id=articleId name=articleId value=17212 /> <input type=hidden id=xmlUrl value="/articles/8-1659/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1659-v1.xml"> <input type=hidden id=article_uuid value=7ec44b77-95d3-46b8-95c8-70e3099647c2 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Microalbuminuria and cardiorenal risk: old and new evidence in different populations"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.17212.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.17212.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1659"
  },
  "headline": "Microalbuminuria and cardiorenal risk: old and new evidence in different populations",
  "datePublished": "2019-09-19T11:11:11",
  "dateModified": "2019-09-19T11:11:11",
  "author": [
    {
      "@type": "Person",
      "name": "Diego Francisco M&aacute;rquez"
    },    {
      "@type": "Person",
      "name": "Gema Ruiz-Hurtado"
    },    {
      "@type": "Person",
      "name": "Julian Segura"
    },    {
      "@type": "Person",
      "name": "Luis Ruilope"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1659.html",
            "name": "Microalbuminuria and cardiorenal risk: old and new evidence in different..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Microalbuminuria and cardiorenal risk: old and new evidence in different... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=18821 data-id=17212 data-downloads="" data-views="" data-scholar="10.12688/f1000research.17212.1" data-recommended="" data-doi="10.12688/f1000research.17212.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1659/v1/pdf?article_uuid=7ec44b77-95d3-46b8-95c8-70e3099647c2" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-17212-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-17212-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-17212-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Márquez DF, Ruiz-Hurtado G, Segura J and Ruilope L. Microalbuminuria and cardiorenal risk: old and new evidence in different populations [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1659 (<a class=new-orange href="https://doi.org/10.12688/f1000research.17212.1" target=_blank>https://doi.org/10.12688/f1000research.17212.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-17212-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=17212 id=track-article-signin-17212 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/17212?target=/articles/8-1659.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=18821 /> <input name=articleId type=hidden value=17212 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Microalbuminuria and cardiorenal risk: old and new evidence in different populations</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:diegomarquez1@yahoo.com.ar" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Diego Francisco M&aacute;rquez</span></a><sup>1</sup>,&nbsp;</span><span class="">Gema Ruiz-Hurtado<sup>2</sup>,&nbsp;</span><span class="">Julian Segura<sup>2</sup>,&nbsp;</span><span class="">Luis Ruilope<a href="https://orcid.org/0000-0001-6278-7951" target=_blank id=author-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6278-7951</div><sup>2-4</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:diegomarquez1@yahoo.com.ar" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Diego Francisco M&aacute;rquez</span></a><sup>1</sup>,&nbsp;</span><span class="">Gema Ruiz-Hurtado<sup>2</sup>,&nbsp;</span><span class="">Julian Segura<sup>2</sup>,&nbsp;</span><span class="">Luis Ruilope<a href="http://orcid.org/0000-0001-6278-7951" target=_blank id=mauthor-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-6278-7951</div><sup>2-4</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 19 Sep 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.17212.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Unidad de Hipertensi&oacute;n Arterial-Servicio de Cl&iacute;nica M&eacute;dica, Hospital San Bernardo, Salta, Argentina<br/> <sup>2</sup> Instituto de Investigaci&oacute;n Imas12 and Unidad de Hipertensi&oacute;n, Hospital 12 de Octubre, Madrid, Spain<br/> <sup>3</sup> Departamento de Medicina Preventiva y Salud P&uacute;blica, Universidad Aut&oacute;noma, Madrid, Spain<br/> <sup>4</sup> Escuela de Estudios Postdoctorales and Investigaci&oacute;n, Universidad de Europa de Madrid, Madrid, Spain<br/> <p> <div class=margin-bottom> Diego Francisco M&aacute;rquez <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Gema Ruiz-Hurtado <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Julian Segura <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Luis Ruilope <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=56274-53131></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=49701-47436></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Since the association of microalbuminuria (MAU) with cardiovascular (CV) risk was described, a huge number of reports have emerged. MAU is a specific integrated marker of CV risk and targets organ damage in patients with hypertension, chronic kidney disease (CKD), and diabetes and its recognition is important for identifying patients at a high or very high global CV risk. The gold standard for diagnosis is albumin measured in 24-hour urine collection (normal values of less than 30 mg/day, MAU of 30 to 300 mg/day, macroalbuminuria of more than 300 mg/day) or, more practically, the determination of urinary albumin-to-creatinine ratio in a urine morning sample (30 to 300 mg/g). MAU screening is mandatory in individuals at risk of developing or presenting elevated global CV risk. Evidence has shown that intensive treatment could turn MAU into normoalbuminuria. Intensive treatment with the administration of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, in combination with other anti-hypertensive drugs and drugs covering other aspects of CV risk, such as mineralocorticoid receptor antagonists, new anti-diabetic drugs, and statins, can diminish the risk accompanying albuminuria in hypertensive patients with or without CKD and diabetes. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> albuminuria, cardiovascular risk, chronic kidney disease </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Diego Francisco M&aacute;rquez (<a href="mailto:diegomarquez1@yahoo.com.ar">diegomarquez1@yahoo.com.ar</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Diego Francisco Márquez </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Márquez DF <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Márquez DF, Ruiz-Hurtado G, Segura J and Ruilope L. Microalbuminuria and cardiorenal risk: old and new evidence in different populations [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1659 (<a href="https://doi.org/10.12688/f1000research.17212.1" target=_blank>https://doi.org/10.12688/f1000research.17212.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 19 Sep 2019, <b>8</b>(F1000 Faculty Rev):1659 (<a href="https://doi.org/10.12688/f1000research.17212.1" target=_blank>https://doi.org/10.12688/f1000research.17212.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 19 Sep 2019, <b>8</b>(F1000 Faculty Rev):1659 (<a href="https://doi.org/10.12688/f1000research.17212.1" target=_blank>https://doi.org/10.12688/f1000research.17212.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e197>Introduction</h2><p class="" id=d28749e200>Mogensen was the first to describe the importance of microalbuminuria (MAU) not only as a renal risk factor but also as a powerful predictor of cardiovascular (CV) mortality in patients with type 2 diabetes mellitus (T2DM)<sup><a href="#ref-1">1</a></sup>. Since the description by Mogensen, MAU has received special attention as a prognostic marker for CV or renal risk or both, even in non-diabetic subjects<sup><a href="#ref-2">2</a></sup>. Mounting evidence indicates a continuous relationship between urinary albumin excretion (UAE) and cardiorenal risk, similar to the relationship between blood pressure (BP) and risk of CV events<sup><a href="#ref-3">3</a>–<a href="#ref-6">6</a></sup>.</p><p class="" id=d28749e218>The presence of MAU implies dysfunction of the glomerular filtration barrier, which may result from hemodynamic-mediated mechanisms, functional or structural impairment of the glomerular barrier, or a combination of these<sup><a href="#ref-7">7</a></sup>. In normal conditions, UAE can change in day-to-day measurements. Moreover, age, sex, body mass index, a high-protein meal, and vigorous exercise can promote a transient increase in albumin excretion. On the other hand, pathological conditions such as fever, congestive heart failure, urinary tract infection, and some drugs can also increase albumin excretion, so we have to consider all of these confounding factors when analyzing the urinary excretion of albumin<sup><a href="#ref-8">8</a></sup>.</p><p class="" id=d28749e229>When MAU is present in pathological conditions, such as chronic kidney disease (CKD), diabetes, or hypertension (HTN), it represents the existence of renal target organ damage and is also a marker of CV morbidity and mortality and of progressive CKD. In this article, we will review the importance of MAU recognition and the management of this marker of cardiorenal risk.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e235>Microalbuminuria diagnosis</h2><p class="" id=d28749e238>There are different types of analysis to assess the presence of MAU. The urine dipstick, an insensitive marker for albuminuria, does not become positive until albumin excretion exceeds 300 to 500 mg/day. In normal conditions, UAE is less than 30 mg/day. When this value oscillates between 30 and 300 mg/day in a 24-hour urine collection or 30 to 300 mg/g of creatinine (urine albumin-to-creatinine ratio, or UACR) in a first morning sample, we used the term MAU, also known as “moderately increased albuminuria”. When albuminuria is more than 300 mg/day, it is considered macroalbuminuria<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Although 24-hour urine collection is the gold standard for the detection of MAU, it has been suggested that screening can be carried out more simply. MAU can be tested from a first morning urine sample or at any time. In recent years, the albumin-to-creatinine ratio (ACR) from spot urine, preferably that first voided in the morning, may be considered equivalent to the values during a 24-hour urine collection<sup><a href="#ref-7">7</a>,<a href="#ref-10">10</a>–<a href="#ref-12">12</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e261>Microalbuminuria in different populations</h2><div class=section><a name=d28749e264 class=n-a></a><h3 class=section-title>General “healthy” population</h3><p class="" id=d28749e269>The prevalence of MAU in the general population varies from 2.2 to 11.8% in different studies<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. In the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study, a representation of the general population from Groningen (The Netherlands) participated in a survey through a postal questionnaire and a vial to collect an early-morning urine sample to determine MAU. A total of 40,856 subjects (47.8%) responded. MAU was present in 7.2% of the subjects, and after exclusion of the diabetic and hypertensive subjects, MAU was still prevalent in 6.6% of the subjects<sup><a href="#ref-13">13</a></sup>. Data from the US National Health and Nutrition Examination Survey (NHANES) showed an increase in prevalence of MAU (ACR of 30 to 300 mg/g) from 7.1 to 8.2% during the survey periods 1988 to 1994 and 1999 to 2004. The increase was attributed to older age of the population, prevalence of HTN and diabetes, and higher body mass index<sup><a href="#ref-15">15</a></sup>. MAU in a “healthy population” is not a benign condition, and the evidence has shown an association between MAU and increased CV risk and all-cause mortality<sup><a href="#ref-16">16</a>–<a href="#ref-20">20</a></sup>. In the above-mentioned PREVEND study<sup><a href="#ref-13">13</a></sup>, UAE is a predictor of all-cause mortality in the general population<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. The Framingham Offspring Study of 1568 non-diabetic and non-hypertensive participants, which showed that low levels of UACR well below the current MAU threshold were associated with greater risk of CV disease (CVD), predicted the development of CVD (hazard ratio [HR] 1.36, 95% confidence interval [CI] 1 to 1.87) and of death (HR 1.55, 95% CI 1.10 to 2.20)<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d28749e310>Moreover, the presence of MAU was associated with increased risk of incident HTN and also diabetes<sup><a href="#ref-21">21</a>–<a href="#ref-24">24</a></sup>. There is strong evidence that the relationship between MAU and other CV risk factors, such as diabetes, HTN, left ventricular hypertrophy, hyperlipidemia, overweight, and metabolic syndrome, contributes to an increase in CV mortality<sup><a href="#ref-6">6</a>,<a href="#ref-25">25</a></sup>.</p></div><div class=section><a name=d28749e328 class=n-a></a><h3 class=section-title>Patients with diabetes</h3><p class="" id=d28749e333>The classic definition of diabetic nephropathy is the presence of MAU that normally appears 5 to 10 years after the diagnosis of diabetes and that without adequate treatment progresses to end-stage renal disease (ESRD)<sup><a href="#ref-26">26</a></sup>. The cumulative incidences of MAU in patients with type 1 diabetes mellitus (T1DM) were 12.6% over 7.3 years, according to the European Diabetes (EURODIAB) Prospective Complications Study Group<sup><a href="#ref-27">27</a></sup>, and 33% in an 18-year follow-up study in Denmark<sup><a href="#ref-28">28</a></sup>. In patients with T2DM, the incidence of MAU showed an increase of 2.0% per year with a prevalence of 25% 10 years after diagnosis in the UK Prospective Diabetes Study (UKPDS)<sup><a href="#ref-26">26</a>,<a href="#ref-29">29</a></sup>. Based on UAE values, diabetic nephropathy has been categorized into stages: MAU and macroalbuminuria. Cumulative evidence suggests that the risk for developing diabetic nephropathy and CVD starts when UAE values are still within the normoalbuminuric range<sup><a href="#ref-30">30</a>–<a href="#ref-32">32</a></sup>. Although MAU has been considered a risk factor for macroalbuminuria, not all patients progress to this stage and some may regress to normoalbuminuria<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Moreover, recent evidence reported that almost 25% of patients with T2DM and CKD with little or no proteinuria have biopsy-proven diabetic nephropathy and can progress to ESRD. The cause of this change in profile of diabetic nephropathy is unclear<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>.</p><p class="" id=d28749e377>The natural history of diabetic nephropathy in patients with T1DM and T2DM is similar. However, the timing of diabetes diagnosis in T2DM is difficult to assess, and often target organ damage is present when the diagnosis of T2DM is confirmed. T1DM allows a timeline picture of kidney disease progression starting with MAU and proceeds through stages of overt proteinuria, kidney function decline, and end-stage kidney disease<sup><a href="#ref-37">37</a>,<a href="#ref-38">38</a></sup>. Nevertheless, this “classic” progression from MAU to macroalbuminuria is not seen in all patients. In fact, in patients with low levels of MAU (ACR of less than 100 mg/g) maintained for 2 to 3 years, it is possible to revert to normal UAE. Regression of MAU is facilitated by improved glucose, BP, and lipid control<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. On the other hand, epidemiological evidence unequivocally shows that albuminuria is a marker of subclinical renal damage and is associated with the progression of CKD as well as CVD in patients with diabetes<sup><a href="#ref-29">29</a>,<a href="#ref-32">32</a>,<a href="#ref-39">39</a>–<a href="#ref-41">41</a></sup>. The relationship between albuminuria and decline of glomerular filtration rate (GFR) has been documented in many studies<sup><a href="#ref-26">26</a></sup>. In a 4-year study that included 194 Pima Indians with T2DM, the rate of GFR decreased by 3% in those with MAU at baseline (<i>P</i> = 0.29) and by 35% in those with macroalbuminuria (<i>P</i> &lt;0.001)<sup><a href="#ref-38">38</a></sup>. Ninomiya <i>et al</i>. showed that T2DM patients with both a UACR of 300 mg/g and an estimated GFR (eGFR) of less than 60 mL/minute per 1.73 m<sup>2</sup> had a 3.2-fold higher risk for CV events and a 22.2-fold higher risk for renal events compared with patients with neither of these risk factors<sup><a href="#ref-42">42</a></sup>. These findings are similar in other ethnic patients with diabetes<sup><a href="#ref-43">43</a></sup>.</p><p class="" id=d28749e436>In an interesting study published recently, Minutolo <i>et al</i>.<sup><a href="#ref-44">44</a></sup> compared the risk of all-cause mortality, fatal and non-fatal CV events, and ESRD between CKD patients with (n = 693) and without (n = 1481) diabetes. The authors stratified participants according to proteinuria level (&lt;0.15, 0.15 to 0.49, 0.5 to 1, and &gt;1 g/day). During 4 years of follow-up, in the subgroup with UAE of less than 0.15 g/day, the risks of ESRD, CV events, and mortality were similar in diabetic and non-diabetic patients. Conversely, in patients with diabetes and CKD, the mortality risk was higher in patients with albuminuria of 0.15 to 0.49 g/day (HR 1.92, 95% CI 1.25 to 2.95), 0.5 to 1 g/day (1.99, 95% CI 1.26 to 3.15), and more than 1 g/day (1.98, 95% CI 1.28 to 3.06)<sup><a href="#ref-44">44</a></sup>.</p></div><div class=section><a name=d28749e451 class=n-a></a><h3 class=section-title>Arterial hypertension</h3><p class="" id=d28749e456>HTN is an established risk factor of CV and all-cause mortality<sup><a href="#ref-45">45</a>–<a href="#ref-47">47</a></sup>. The prevalence of MAU in arterial HTN varies in different studies, ranging from 8 to 15%<sup><a href="#ref-48">48</a>–<a href="#ref-51">51</a></sup>. However, in some studies, the prevalence was much higher<sup><a href="#ref-52">52</a></sup> and this wide difference may be due to differences in urine collection, cutoff level of normal albumin excretion, analytical methods, and the presence of anti-hypertensive medications.</p><p class="" id=d28749e477>Many studies have shown an association between MAU and BP circadian profile<sup><a href="#ref-53">53</a>–<a href="#ref-55">55</a></sup>. Ambulatory BP monitoring has shown that nighttime BP levels are associated with MAU<sup><a href="#ref-56">56</a></sup> and were a better predictor of major adverse CV events than office BP and 24-hour or daytime levels<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>. In the general population, sustained HTN was associated with albuminuria. Moreover, the Hisayama study showed the association of white coat HTN and masked HTN with albuminuria in the general Japanese population<sup><a href="#ref-59">59</a></sup>. Similar findings were found for masked HTN<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup>. In resistant hypertensive patients, Oliveras <i>et al</i>. found that true resistant HTN was associated with silent target organ damage, especially albuminuria<sup><a href="#ref-62">62</a></sup>.</p><p class="" id=d28749e517>The European guidelines for HTN emphasize the importance of assessing the presence of organ damage for CV risk stratification, including the estimation of albuminuria<sup><a href="#ref-63">63</a></sup>. So it is very important that physicians look for the presence of MAU or subclinical renal involvement in patients with HTN to better assess CV risk stratification and develop strategies to control BP and reduced proteinuria<sup><a href="#ref-64">64</a></sup>.</p></div><div class=section><a name=d28749e529 class=n-a></a><h3 class=section-title>Target organ damage</h3><p class="" id=d28749e534>Different authors found an association between MAU as a marker of subclinical organ damage in non-diabetic hypertensive patients. The presence of MAU in patients with HTN was associated with a higher prevalence of left ventricular geometric patterns, especially concentric hypertrophy, assessed by either electrocardiography or echocardiography, compared with normoalbuminurics<sup><a href="#ref-65">65</a>–<a href="#ref-67">67</a></sup>. The presence of MAU is also associated with several vascular structural and functional alterations<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>, such as higher thickness of the intima and media of carotid artery compared with patients with normoalbuminuria<sup><a href="#ref-70">70</a></sup>, and predicts the development and progression of carotid atherosclerosis<sup><a href="#ref-71">71</a></sup>.</p><p class="" id=d28749e559>MAU was also associated with retinal vascular damage in patients with HTN<sup><a href="#ref-72">72</a></sup>. In patients with T1DM, MAU is a powerful predictor for the development of proliferative diabetic retinopathy and blindness<sup><a href="#ref-73">73</a></sup>. MAU was also identified as a marker of coronariopathy in diabetic and non-diabetic patients and in the general population and as a marker of cardiac dysfunction<sup><a href="#ref-74">74</a>–<a href="#ref-77">77</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e581>Chronic kidney disease</h2><p class="" id=d28749e584>CKD is recognized as a major global public health problem<sup><a href="#ref-3">3</a>,<a href="#ref-78">78</a></sup>. CKD affects 10 to 16% of the adult population and is an important risk factor for CVD events, particularly when albuminuria is present<sup><a href="#ref-3">3</a></sup>. Available clinical practice guidelines have emphasized the use of current level of albuminuria as well as eGFR for CKD definition and staging<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. Different studies have shown the detrimental role that albuminuria plays in CKD progression and CV mortality in these populations<sup><a href="#ref-81">81</a></sup>. Sumida <i>et al</i>. showed, in a cohort of 56,946 US veterans with eGFR of more than 60 mL/minute per 1.73 m<sup>2</sup>, that relative changes in albuminuria over a 1-year interval were linearly associated with subsequent risk of kidney outcomes<sup><a href="#ref-82">82</a></sup>. Similarly, in patients with diabetes, MAU and macroalbuminuria are associated with higher risks of CVD and of reduced eGFR compared with normoalbuminuria<sup><a href="#ref-83">83</a></sup>.</p><p class="" id=d28749e624>As the worsening of albuminuria leads to CKD progression, its reduction with specific treatment leads to improving kidney function, so that albuminuria could be considered a therapeutic target in clinical practice and a surrogate endpoint for ESRD<sup><a href="#ref-84">84</a>,<a href="#ref-85">85</a></sup>. In the Stockholm CREAtinine Measurements (SCREAM) project, 31,732 individuals were studied with two or more ambulatory ACR tests to assess changes between ACR, ESRD, or death. Compared with stable ACR, a fourfold increase in ACR was associated with a 3.08-fold (95% CI 2.59 to 3.67) higher risk of ESRD and mortality, whereas a fourfold decrease in ACR was associated with a 0.34-fold (0.26 to 0.45) lower risk of ESRD<sup><a href="#ref-86">86</a></sup>. Different authors have documented mortality and morbidity associated with albuminuria changes<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>.</p><p class="" id=d28749e645>In kidney transplant recipients, Weiner <i>et al</i>. recently reported that the presence of albuminuria (MAU and macroalbuminuria) in kidney transplant recipients was strongly associated with graft failure, CVD events, and death<sup><a href="#ref-89">89</a></sup>. This association is similar to that seen between albuminuria outcomes in the general population<sup><a href="#ref-89">89</a></sup>.</p><p class="" id=d28749e659>In recent decades, the BP target for hypertensive patients with CKD and proteinuria has been changing constantly. A few years ago, the recommended BP targets for the CKD population were less than 140/90 mm Hg and, if albuminuria was present, less than 130/80 mm Hg<sup><a href="#ref-79">79</a>,<a href="#ref-90">90</a>–<a href="#ref-92">92</a></sup>. The publication of the Systolic Blood Pressure Intervention Trial (SPRINT) in 2015 contributed to the consideration of a lower BP goal in non-diabetic CKD<sup><a href="#ref-93">93</a></sup>. SPRINT is a landmark study that randomly assigned 9361 persons without diabetes to a systolic BP (SBP) target of less than 120 mm Hg (intensive treatment) versus an SBP of less than 140 mm Hg (standard treatment). The authors concluded that targeting an SBP of less than 120 mm Hg, compared with less than 140 mm Hg, resulted in lower rates of fatal and non-fatal major CV events and death from any cause<sup><a href="#ref-93">93</a></sup>. In that trial, 28% of the study population had CKD (eGFR of 20 to less than 60 mL/minute per 1.73 m<sup>2</sup>), and in that group, intensive BP management seemed to provide the same benefits for reduction in the CVD composite primary outcome and all-cause mortality as were seen in the full study cohort<sup><a href="#ref-93">93</a></sup>. Given that most patients with CKD die from CVD complications, SPRINT evidence supports a lower target of less than 130/80 mm Hg for all patients with CKD<sup><a href="#ref-93">93</a>,<a href="#ref-94">94</a></sup>. However, observational studies of CKD cohorts indicate a higher risk of mortality at lower systolic pressures in elderly patients with CKD<sup><a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>. In contrast, in the pre-specified subgroup analysis of the elderly cohort in SPRINT, frail elderly patients did sustain benefit from the lower BP target, which supports a lower goal for all patients, including those with CKD<sup><a href="#ref-97">97</a></sup>. In contrast, data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study indicate that strict BP control (SBP of less than 120 mm Hg) did not improve renal outcomes in patients with T2DM<sup><a href="#ref-98">98</a></sup>. Since the publication of SPRINT, different guidelines have reviewed the BP target in the CKD population and support the BP target of less than 130/80 mm Hg for CKD patients independently of the presence of albuminuria<sup><a href="#ref-63">63</a>,<a href="#ref-99">99</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e720>Management of albuminuria: focus on pharmacotherapy</h2><p class="" id=d28749e723>MAU is frequently present in asymptomatic patients. Recently, two meta-analyses assessed albuminuria as a surrogate endpoint for CKD progression in randomized controlled trials<sup><a href="#ref-100">100</a>,<a href="#ref-101">101</a></sup>. Both articles found that the range in albuminuria was consistently associated with risk of end-stage kidney disease, lending support to the use of change in albuminuria as a surrogate endpoint for end-stage kidney disease<sup><a href="#ref-100">100</a>,<a href="#ref-101">101</a></sup>. Given that MAU as a marker of target organ damage is associated with CV mortality and CKD progression, it is important to treat these patients intensively.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e744>Renin–angiotensin–aldosterone system blockade intervention trials</h2><p class="" id=d28749e747>Reduction of albuminuria under anti-hypertensive treatment is associated with reduced risk of clinical CV events and at the same time renal protection<sup><a href="#ref-102">102</a>,<a href="#ref-103">103</a></sup>. There is cumulative evidence of the efficacy of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) for the treatment of HTN in this population<sup><a href="#ref-63">63</a>,<a href="#ref-99">99</a>,<a href="#ref-104">104</a>,<a href="#ref-105">105</a></sup>. A few trials that focus the intervention on MAU have been designed. In the Action in Diabetes and Vascular Disease (ADVANCE) trial, perindopril/indapamide was effective in preventing the onset of MAU, progression of MAU to macroalbuminuria, and even regression of albuminuria compared with placebo in patients with T2DM<sup><a href="#ref-106">106</a></sup>. Similarly, in the Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial, olmesartan diminished the onset of MAU by 23% in T2DM<sup><a href="#ref-107">107</a></sup>. Dual renin–angiotensin–aldosterone system (RAAS) blockade between an ACEi plus an ARB should be avoided<sup><a href="#ref-63">63</a>,<a href="#ref-99">99</a></sup>. This combination showed more cases of acute kidney injury and hyperkalemia without benefits<sup><a href="#ref-108">108</a>,<a href="#ref-109">109</a></sup>. A similar result was found with the addition of the direct renin inhibitor aliskiren to an ACEi or ARB<sup><a href="#ref-110">110</a></sup>. The combination of the standard therapy with an ACEi or an ARB with a mineralocorticoid receptor antagonist (MRA) is an interesting option for managing patients with albuminuria but has the inconvenience of frequent hyperkalemia in patients with CKD<sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup>. In order to avoid the limitations of hyperkalemia of the traditional RAAS blockers in patients with CKD, new drugs have been developed<sup><a href="#ref-113">113</a></sup>. The new non-steroidal MRA finerenone (BAY948862) has better MRA selectivity than spironolactone and also reduced albuminuria and end organ damage more effectively than eplerenone<sup><a href="#ref-114">114</a></sup>. In the MinerAlocorticoid Receptor Antagonist Tolerability Study (ARTS), finerenone reduced albuminuria from baseline levels and had a lower incidence of hyperkalemia when compared with spironolactone in patients with chronic heart failure<sup><a href="#ref-115">115</a></sup>. Moreover, in the MinerAlocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) study, different oral doses of finerenone in patients with T2DM reduced albuminuria<sup><a href="#ref-116">116</a></sup>. The addition of the new potassium binder patiromer<sup><a href="#ref-117">117</a></sup> and the selective cation exchanger sodium zirconium cyclosilicate<sup><a href="#ref-118">118</a></sup> facilitated the use of traditional MRA in patients with CKD, reducing potassium levels<sup><a href="#ref-119">119</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e836>Glucose-lowering agents</h2><p class="" id=d28749e839>In recent years, new anti-diabetic agents appeared not only showing benefits in glycemic control but also reducing CV mortality and improving kidney function. The SGLT2 inhibitor acts as a glycosuric agent. In the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME), empagliflozin or placebo was added to standard care in patients with T2DM and CVD<sup><a href="#ref-120">120</a></sup>. Empagliflozin reduced new or worsening nephropathy, doubling of serum creatinine (1.5% of the empagliflozin versus 2.6% placebo; <i>P</i> &lt;0.001%), and progression to macroalbuminuria (11.2% empagliflozin versus 16.2% placebo; <i>P</i> &lt;0.001%)<sup><a href="#ref-121">121</a></sup>. Similarly, in the CANagliflozin cardioVascular Assessment Study (CANVAS), canagliflozin or placebo was added to standard care in patients with T2DM with CVD or at high risk of CVD<sup><a href="#ref-122">122</a></sup>. Active treatment with canagliflozin slowed the rate of eGFR decline and reduced UACR. Doubling of serum creatinine and new-onset macroalbuminuria were significantly reduced<sup><a href="#ref-122">122</a></sup>.</p><p class="" id=d28749e865>Moreover, in the recently published Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy study (CREDENCE), patients with T2DM and CKD were randomly assigned to receive canagliflozin or placebo<sup><a href="#ref-123">123</a></sup>. The study was ended earlier because of recommendations from the safety committee. After 2.62 years, 4401 patients were randomly assigned. The event rates in the canagliflozin group and the placebo group were 43.2 and 61.2 per 1000 patient-years, respectively (HR 0.70, 95% CI 0.59 to 0.82; <i>P</i> = 0.00001), and the relative risk of the primary outcome was 30% lower in the canagliflozin group. The relative risk of end-stage kidney disease was lower by 32% (HR 0.68, 95% CI 0.54 to 0.86; <i>P</i> = 0.002), and the relative risks of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes were lower by 34% (HR 0.66, 95% CI 0.53 to 0.81; <i>P</i> &lt;0.001). The canagliflozin group had lower risks of hospitalization for heart failure (HR 0.61, 95% CI 0.47 to 0.80; <i>P</i> &lt;0.001) and CV death, myocardial infarction, or stroke (HR 0.80, 95% CI 0.67 to 0.95; <i>P</i> = 0.01)<sup><a href="#ref-123">123</a></sup>.</p><p class="" id=d28749e892>Two multicenter phase III trials with SGLT2 inhibitor looking for renal and CV endpoints are ongoing: the EMPA-Kidney with empaglifozin (ClinicalTrials.gov Identifier: NCT03594110) and the Dapa-CKD with canagliflozin (ClinicalTrials.gov Identifier: NCT03036150). Both studies aim to investigate the effect of SGLT2 inhibitors on kidney disease progression or CV death versus placebo.</p><p class="" id=d28749e895>GLP-1 agonists liraglutide<sup><a href="#ref-124">124</a></sup> and semaglutide<sup><a href="#ref-125">125</a></sup> have also shown a significant improvement in CV outcomes of patients with T2DM and were accompanied by a more significant decrease in body weight and a less important drop in BP in the absence of natriuretic effects. This last point could explain the absence of effects on heart failure. Liraglutide also exhibited a renal protective capacity through a significant decrease in albuminuria<sup><a href="#ref-126">126</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e913>Endothelin receptor antagonists</h2><p class="" id=d28749e916>Endothelin receptor antagonists reduce albuminuria and BP but can also cause sodium retention. A previous trial with the non-selective endothelin receptor antagonist avosentan in patients with diabetes and CKD was stopped prematurely because of an increased incidence of heart failure<sup><a href="#ref-127">127</a></sup>. By contrast, short-term treatment with low doses of the more selective endothelin A receptor antagonist atrasentan reduced albuminuria without causing significant fluid retention<sup><a href="#ref-128">128</a>,<a href="#ref-129">129</a></sup>. Recently, the Study of Diabetic Nephropathy with Atrasentan (SONAR) was published and showed a reduction in the risk of renal events with no significant differences for hospitalization for heart failure and also mortality compared with placebo<sup><a href="#ref-130">130</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e937>Statins and fibrates</h2><p class="" id=d28749e940>Drugs other than anti-hypertensives can influence MAU and renal function. Different meta-analyses showed reductions of MAU, proteinuria, and clinical deaths with statins<sup><a href="#ref-131">131</a>–<a href="#ref-133">133</a></sup>. Fibrates showed also a reduction in albuminuria<sup><a href="#ref-134">134</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28749e957>Conclusions</h2><p class="" id=d28749e960>MAU is a specific integrated marker of CV risk and target organ damage in patients with HTN, CKD, and diabetes and its recognition is important for identifying patients at higher risk for CV mortality. The determination of albumin in 24-hour urine collection is the gold standard, but screening is usually made with the UACR (30 to 300 mg/g) in the first voiding urine. Using ACEi or ARB in these patients is recommended and recently more strategies for its management, such as the new anti-diabetic drugs or the novel MRA, have become available. At the moment, diagnosis of MAU is challenging because of the possibility of returning to normoalbuminuria with intensive treatment.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d28749e967 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d29599>References</h2><div class="section ref-list"><a name=d28749e967 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718739657"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e974 class=n-a></a>Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. <i>N Engl J Med.</i> 1984; <b>310</b>(6): 356–60. <a target=xrefwindow id=d28749e982 href="http://www.ncbi.nlm.nih.gov/pubmed/6690964">PubMed Abstract </a> | <a target=xrefwindow id=d28749e985 href="https://doi.org/10.1056/NEJM198402093100605">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718739657">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727020443"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e998 class=n-a></a>Mulè G, Castiglia A, Cusumano C, <i> et al.</i>: Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. <i>Adv Exp Med Biol.</i> 2017; <b>956</b>: 279–306. <a target=xrefwindow id=d28749e1009 href="http://www.ncbi.nlm.nih.gov/pubmed/27873229">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1012 href="https://doi.org/10.1007/5584_2016_85">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727020443">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d28749e1025 class=n-a></a>Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, <i> et al.</i>: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. <i>Lancet.</i> 2010; <b>375</b>(9731): 2073–81. <a target=xrefwindow id=d28749e1036 href="http://www.ncbi.nlm.nih.gov/pubmed/20483451">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1039 href="https://doi.org/10.1016/S0140-6736(10)60674-5">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3993088">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d28749e1052 class=n-a></a>Ruilope LM: The kidney as a sensor of cardiovascular risk in essential hypertension. <i>J Am Soc Nephrol.</i> 2002; <b>13 Suppl 3</b>: S165–8. <a target=xrefwindow id=d28749e1060 href="http://www.ncbi.nlm.nih.gov/pubmed/12466307">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1063 href="https://doi.org/10.1097/01.asn.0000034496.63958.f8">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d28749e1072 class=n-a></a>Arnlöv J, Evans JC, Meigs JB, <i> et al.</i>: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. <i>Circulation.</i> 2005; <b>112</b>(7): 969–75. <a target=xrefwindow id=d28749e1083 href="http://www.ncbi.nlm.nih.gov/pubmed/16087792">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1086 href="https://doi.org/10.1161/CIRCULATIONAHA.105.538132">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d28749e1096 class=n-a></a>Weir MR: Microalbuminuria and cardiovascular disease. <i>Clin J Am Soc Nephrol.</i> 2007; <b>2</b>(3): 581–90. <a target=xrefwindow id=d28749e1104 href="http://www.ncbi.nlm.nih.gov/pubmed/17699466">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1107 href="https://doi.org/10.2215/CJN.03190906">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d28749e1116 class=n-a></a>Levey AS, Cattran D, Friedman A, <i> et al.</i>: Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. <i>Am J Kidney Dis.</i> 2009; <b>54</b>(2): 205–26. <a target=xrefwindow id=d28749e1127 href="http://www.ncbi.nlm.nih.gov/pubmed/19577347">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1130 href="https://doi.org/10.1053/j.ajkd.2009.04.029">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d28749e1139 class=n-a></a>Mogensen CE, Vestbo E, Poulsen PL, <i> et al.</i>: Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. <i>Diabetes Care.</i> 1995; <b>18</b>(4): 572–81. <a target=xrefwindow id=d28749e1150 href="http://www.ncbi.nlm.nih.gov/pubmed/7497874">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1153 href="https://doi.org/10.2337/diacare.18.4.572">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d28749e1162 class=n-a></a>Howey JE, Browning MC, Fraser CG: Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. <i>Clin Chem.</i> 1987; <b>33</b>(11): 2034–8. <a target=xrefwindow id=d28749e1170 href="http://www.ncbi.nlm.nih.gov/pubmed/3677375">PubMed Abstract </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d28749e1179 class=n-a></a>Witte EC, Lambers Heerspink HJ, de Zeeuw D, <i> et al.</i>: First morning voids are more reliable than spot urine samples to assess microalbuminuria. <i>J Am Soc Nephrol.</i> 2009; <b>20</b>(2): 436–43. <a target=xrefwindow id=d28749e1190 href="http://www.ncbi.nlm.nih.gov/pubmed/19092125">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1193 href="https://doi.org/10.1681/ASN.2008030292">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1197 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2637059">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d28749e1206 class=n-a></a>Miller WG, Bruns DE, Hortin GL, <i> et al.</i>: Current issues in measurement and reporting of urinary albumin excretion. <i>Clin Chem.</i> 2009; <b>55</b>(1): 24–38. <a target=xrefwindow id=d28749e1217 href="http://www.ncbi.nlm.nih.gov/pubmed/19028824">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1220 href="https://doi.org/10.1373/clinchem.2008.106567">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4655956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e1230 class=n-a></a>Lambers Heerspink HJ, Gansevoort RT, Brenner BM, <i> et al.</i>: Comparison of different measures of urinary protein excretion for prediction of renal events. <i>J Am Soc Nephrol.</i> 2010; <b>21</b>(8): 1355–60. <a target=xrefwindow id=d28749e1241 href="http://www.ncbi.nlm.nih.gov/pubmed/20634296">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1244 href="https://doi.org/10.1681/ASN.2010010063">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1248 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2938598">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4655956">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d28749e1261 class=n-a></a>Hillege HL, Janssen WM, Bak AA, <i> et al.</i>: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. <i>J Intern Med.</i> 2001; <b>249</b>(6): 519–26. <a target=xrefwindow id=d28749e1272 href="http://www.ncbi.nlm.nih.gov/pubmed/11422658">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1275 href="https://doi.org/10.1046/j.1365-2796.2001.00833.x">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d28749e1284 class=n-a></a>Yuyun MF, Khaw KT, Luben R, <i> et al.</i>: Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study. <i>Eur J Cardiovasc Prev Rehabil.</i> 2004; <b>11</b>(3): 207–13. <a target=xrefwindow id=d28749e1295 href="http://www.ncbi.nlm.nih.gov/pubmed/15179101">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1298 href="https://doi.org/10.1097/01.hjr.0000133070.75016.1d">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1097214"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e1307 class=n-a></a>Coresh J, Selvin E, Stevens LA, <i> et al.</i>: Prevalence of chronic kidney disease in the United States. <i>JAMA.</i> 2007; <b>298</b>(17): 2038–47. <a target=xrefwindow id=d28749e1318 href="http://www.ncbi.nlm.nih.gov/pubmed/17986697">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1321 href="https://doi.org/10.1001/jama.298.17.2038">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1097214">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d28749e1334 class=n-a></a>Romundstad S, Holmen J, Kvenild K, <i> et al.</i>: Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. <i>Am J Kidney Dis.</i> 2003; <b>42</b>(3): 466–73. <a target=xrefwindow id=d28749e1345 href="http://www.ncbi.nlm.nih.gov/pubmed/12955674">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1348 href="https://doi.org/10.1016/s0272-6386(03)00742-x">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d28749e1357 class=n-a></a>Yuyun MF, Khaw KT, Luben R, <i> et al.</i>: Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. <i>Int J Epidemiol.</i> 2004; <b>33</b>(1): 189–98. <a target=xrefwindow id=d28749e1368 href="http://www.ncbi.nlm.nih.gov/pubmed/15075168">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1371 href="https://doi.org/10.1093/ije/dyh008">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d28749e1381 class=n-a></a>Hillege HL, Fidler V, Diercks GF, <i> et al.</i>: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. <i>Circulation.</i> 2002; <b>106</b>(14): 1777–82. <a target=xrefwindow id=d28749e1392 href="http://www.ncbi.nlm.nih.gov/pubmed/12356629">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1395 href="https://doi.org/10.1161/01.cir.0000031732.78052.81">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733770209"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e1404 class=n-a></a>Chong J, Fotheringham J, Tomson C, <i> et al.</i>: Renal albumin excretion in healthy young adults and its association with mortality risk in the US population. <i>Nephrol Dial Transplant.</i> 2018; <b>375</b>: 2073. <a target=xrefwindow id=d28749e1415 href="http://www.ncbi.nlm.nih.gov/pubmed/30085245">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1418 href="https://doi.org/10.1093/ndt/gfy242">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733770209">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d28749e1431 class=n-a></a>Tanaka F, Komi R, Makita S, <i> et al.</i>: Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. <i>J Hypertens.</i> 2016; <b>34</b>(3): 506–12; discussion 512. <a target=xrefwindow id=d28749e1442 href="http://www.ncbi.nlm.nih.gov/pubmed/26820477">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1445 href="https://doi.org/10.1097/HJH.0000000000000809">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d28749e1454 class=n-a></a>Sung KC, Ryu S, Lee JY, <i> et al.</i>: Urine Albumin/Creatinine Ratio Below 30 mg/g is a Predictor of Incident Hypertension and Cardiovascular Mortality. <i>J Am Heart Assoc.</i> 2016; <b>5</b>(9): pii: e003245. <a target=xrefwindow id=d28749e1465 href="http://www.ncbi.nlm.nih.gov/pubmed/27625343">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1468 href="https://doi.org/10.1161/JAHA.116.003245">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1472 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5079007">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d28749e1481 class=n-a></a>Scheven L, van der Velde M, Lambers Heerspink HJ, <i> et al.</i>: Isolated microalbuminuria indicates a poor medical prognosis. <i>Nephrol Dial Transplant.</i> 2013; <b>28</b>(7): 1794–801. <a target=xrefwindow id=d28749e1492 href="http://www.ncbi.nlm.nih.gov/pubmed/23493327">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1495 href="https://doi.org/10.1093/ndt/gft031">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d28749e1504 class=n-a></a>Takashima N, Ohkubo T, Miura K, <i> et al.</i>: Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. <i>J Hypertens.</i> 2012; <b>30</b>(12): 2299–306. <a target=xrefwindow id=d28749e1515 href="http://www.ncbi.nlm.nih.gov/pubmed/23079682">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1518 href="https://doi.org/10.1097/HJH.0b013e328359a9f7">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d28749e1528 class=n-a></a>Hirayama A, Konta T, Hozawa A, <i> et al.</i>: Slight increase in urinary albumin excretion within the normal range predicts incident hypertension in a community-based Japanese population: the Takahata study. <i>Hypertens Res.</i> 2015; <b>38</b>(1): 56–60. <a target=xrefwindow id=d28749e1539 href="http://www.ncbi.nlm.nih.gov/pubmed/25007767">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1542 href="https://doi.org/10.1038/hr.2014.117">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d28749e1551 class=n-a></a>de Zeeuw D, Parving HH, Henning RH: Microalbuminuria as an early marker for cardiovascular disease. <i>J Am Soc Nephrol.</i> 2006; <b>17</b>(8): 2100–5. <a target=xrefwindow id=d28749e1559 href="http://www.ncbi.nlm.nih.gov/pubmed/16825327">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1562 href="https://doi.org/10.1681/ASN.2006050517">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d28749e1571 class=n-a></a>Marshall SM: Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus. <i>Adv Chronic Kidney Dis.</i> 2014; <b>21</b>(3): 267–72. <a target=xrefwindow id=d28749e1579 href="http://www.ncbi.nlm.nih.gov/pubmed/24780454">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1582 href="https://doi.org/10.1053/j.ackd.2014.03.007">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d28749e1591 class=n-a></a>Chaturvedi N, Bandinelli S, Mangili R, <i> et al.</i>: Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. <i>Kidney Int.</i> 2001; <b>60</b>(1): 219–27. <a target=xrefwindow id=d28749e1602 href="http://www.ncbi.nlm.nih.gov/pubmed/11422754">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1605 href="https://doi.org/10.1046/j.1523-1755.2001.00789.x">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d28749e1614 class=n-a></a>Hovind P, Tarnow L, Rossing P, <i> et al.</i>: Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. <i>BMJ.</i> 2004; <b>328</b>(7448): 1105. <a target=xrefwindow id=d28749e1625 href="http://www.ncbi.nlm.nih.gov/pubmed/15096438">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1628 href="https://doi.org/10.1136/bmj.38070.450891.FE">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1632 href="http://www.ncbi.nlm.nih.gov/pmc/articles/406322">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d28749e1641 class=n-a></a>Adler AI, Stevens RJ, Manley SE, <i> et al.</i>: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). <i>Kidney Int.</i> 2003; <b>63</b>(1): 225–32. <a target=xrefwindow id=d28749e1652 href="http://www.ncbi.nlm.nih.gov/pubmed/12472787">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1655 href="https://doi.org/10.1046/j.1523-1755.2003.00712.x">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d28749e1665 class=n-a></a>de Boer IH, Afkarian M, Rue TC, <i> et al.</i>: Renal outcomes in patients with type 1 diabetes and macroalbuminuria. <i>J Am Soc Nephrol.</i> 2014; <b>25</b>(10): 2342–50. <a target=xrefwindow id=d28749e1676 href="http://www.ncbi.nlm.nih.gov/pubmed/24925722">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1679 href="https://doi.org/10.1681/ASN.2013091004">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1683 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4178441">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d28749e1692 class=n-a></a>de Boer IH, Rue TC, Cleary PA, <i> et al.</i>: Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. <i>Arch Intern Med.</i> 2011; <b>171</b>(5): 412–20. <a target=xrefwindow id=d28749e1703 href="http://www.ncbi.nlm.nih.gov/pubmed/21403038">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1706 href="https://doi.org/10.1001/archinternmed.2011.16">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1710 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3085024">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d28749e1719 class=n-a></a>de Zeeuw D, Remuzzi G, Parving HH, <i> et al.</i>: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. <i>Kidney Int.</i> 2004; <b>65</b>(6): 2309–20. <a target=xrefwindow id=d28749e1730 href="http://www.ncbi.nlm.nih.gov/pubmed/15149345">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1733 href="https://doi.org/10.1111/j.1523-1755.2004.00653.x">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d28749e1742 class=n-a></a>Perkins BA, Ficociello LH, Silva KH, <i> et al.</i>: Regression of microalbuminuria in type 1 diabetes. <i>N Engl J Med.</i> 2003; <b>348</b>(23): 2285–93. <a target=xrefwindow id=d28749e1753 href="http://www.ncbi.nlm.nih.gov/pubmed/12788992">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1756 href="https://doi.org/10.1056/NEJMoa021835">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d28749e1765 class=n-a></a>Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? <i>Diabetes.</i> 2000; <b>49</b>(9): 1399–408. <a target=xrefwindow id=d28749e1773 href="http://www.ncbi.nlm.nih.gov/pubmed/10969821">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1776 href="https://doi.org/10.2337/diabetes.49.9.1399">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d28749e1785 class=n-a></a>Dwyer JP, Lewis JB: Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. <i>Med Clin North Am.</i> 2013; <b>97</b>(1): 53–8. <a target=xrefwindow id=d28749e1793 href="http://www.ncbi.nlm.nih.gov/pubmed/23290729">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1796 href="https://doi.org/10.1016/j.mcna.2012.10.006">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d28749e1806 class=n-a></a>Koye DN, Magliano DJ, Reid CM, <i> et al.</i>: Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. <i>Am J Kidney Dis.</i> 2018; <b>72</b>(5): 653–61. <a target=xrefwindow id=d28749e1817 href="http://www.ncbi.nlm.nih.gov/pubmed/29784612">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1820 href="https://doi.org/10.1053/j.ajkd.2018.02.364">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d28749e1829 class=n-a></a>Kussman MJ, Goldstein H, Gleason RE: The clinical course of diabetic nephropathy. <i>JAMA.</i> 1976; <b>236</b>(16): 1861–3. <a target=xrefwindow id=d28749e1837 href="http://www.ncbi.nlm.nih.gov/pubmed/989537">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1840 href="https://doi.org/10.1001/jama.1976.03270170027020">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d28749e1849 class=n-a></a>Nelson RG, Bennett PH, Beck GJ, <i> et al.</i>: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. <i>N Engl J Med.</i> 1996; <b>335</b>(22): 1636–42. <a target=xrefwindow id=d28749e1860 href="http://www.ncbi.nlm.nih.gov/pubmed/8929360">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1863 href="https://doi.org/10.1056/NEJM199611283352203">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727294480"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e1872 class=n-a></a>Oellgaard J, Gæde P, Rossing P, <i> et al.</i>: Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. <i>Kidney Int.</i> 2017; <b>91</b>(4): 982–8. <a target=xrefwindow id=d28749e1883 href="http://www.ncbi.nlm.nih.gov/pubmed/28187983">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1886 href="https://doi.org/10.1016/j.kint.2016.11.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727294480">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d28749e1899 class=n-a></a>Umanath K, Lewis JB: Update on Diabetic Nephropathy: Core Curriculum 2018. <i>Am J Kidney Dis.</i> 2018; <b>71</b>(6): 884–95. <a target=xrefwindow id=d28749e1907 href="http://www.ncbi.nlm.nih.gov/pubmed/29398179">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1910 href="https://doi.org/10.1053/j.ajkd.2017.10.026">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d28749e1919 class=n-a></a>Gerstein HC, Mann JF, Yi Q, <i> et al.</i>: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. <i>JAMA.</i> 2001; <b>286</b>(4): 421–6. <a target=xrefwindow id=d28749e1930 href="http://www.ncbi.nlm.nih.gov/pubmed/11466120">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1933 href="https://doi.org/10.1001/jama.286.4.421">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d28749e1943 class=n-a></a>Ninomiya T, Perkovic V, de Galan BE, <i> et al.</i>: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. <i>J Am Soc Nephrol.</i> 2009; <b>20</b>(8): 1813–21. <a target=xrefwindow id=d28749e1954 href="http://www.ncbi.nlm.nih.gov/pubmed/19443635">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1957 href="https://doi.org/10.1681/ASN.2008121270">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1961 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2723977">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d28749e1970 class=n-a></a>Afkarian M, Katz R, Bansal N, <i> et al.</i>: Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study. <i>Clin J Am Soc Nephrol</i> 2016; <b>11</b>(8): 1384–91. <a target=xrefwindow id=d28749e1981 href="http://www.ncbi.nlm.nih.gov/pubmed/27340284">PubMed Abstract </a> | <a target=xrefwindow id=d28749e1984 href="https://doi.org/10.2215/CJN.13111215">Publisher Full Text </a> | <a target=xrefwindow id=d28749e1988 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4974894">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732807032"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e1997 class=n-a></a>Minutolo R, Gabbai FB, Provenzano M, <i> et al.</i>: Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies. <i>Nephrol Dial Transplant.</i> 2018; <b>33</b>(11): 1942–9. <a target=xrefwindow id=d28749e2008 href="http://www.ncbi.nlm.nih.gov/pubmed/29509925">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2011 href="https://doi.org/10.1093/ndt/gfy032">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732807032">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d28749e2024 class=n-a></a>Seo MH, Lee JY, Ryu S, <i> et al.</i>: The Effects of Urinary Albumin and Hypertension on All-Cause and Cardiovascular Disease Mortality in Korea. <i>Am J Hypertens.</i> 2017; <b>30</b>(8): 799–807. <a target=xrefwindow id=d28749e2035 href="http://www.ncbi.nlm.nih.gov/pubmed/28472229">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2038 href="https://doi.org/10.1093/ajh/hpx051">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2042 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5861583">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d28749e2051 class=n-a></a>Ford ES: Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. <i>Circulation.</i> 2011; <b>123</b>(16): 1737–44. <a target=xrefwindow id=d28749e2059 href="http://www.ncbi.nlm.nih.gov/pubmed/21518989">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2062 href="https://doi.org/10.1161/CIRCULATIONAHA.110.005645">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d28749e2071 class=n-a></a>Fujiyoshi A, Ohkubo T, Miura K, <i> et al.</i>: Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. <i>Hypertens Res.</i> 2012; <b>35</b>(9): 947–53. <a target=xrefwindow id=d28749e2082 href="http://www.ncbi.nlm.nih.gov/pubmed/22739419">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2085 href="https://doi.org/10.1038/hr.2012.87">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d28749e2095 class=n-a></a>Høegholm A, Bang LE, Kristensen KS, <i> et al.</i>: Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. <i>Hypertension.</i> 1994; <b>24</b>(1): 101–5. <a target=xrefwindow id=d28749e2106 href="http://www.ncbi.nlm.nih.gov/pubmed/8020997">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2109 href="https://doi.org/10.1161/01.hyp.24.1.101">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d28749e2118 class=n-a></a>Palatini P, Graniero GR, Mormino P, <i> et al.</i>: Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study). <i>Am J Hypertens.</i> 1996; <b>9</b>(4 Pt 1): 334–41. <a target=xrefwindow id=d28749e2129 href="http://www.ncbi.nlm.nih.gov/pubmed/8722436">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2132 href="https://doi.org/10.1016/0895-7061(95)00391-6">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d28749e2141 class=n-a></a>Pontremoli R, Sofia A, Ravera M, <i> et al.</i>: Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. <i>Hypertension.</i> 1997; <b>30</b>(5): 1135–43. <a target=xrefwindow id=d28749e2152 href="http://www.ncbi.nlm.nih.gov/pubmed/9369267">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2155 href="https://doi.org/10.1161/01.hyp.30.5.1135">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d28749e2164 class=n-a></a>Jones CA, Francis ME, Eberhardt MS, <i> et al.</i>: Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. <i>Am J Kidney Dis.</i> 2002; <b>39</b>(3): 445–59. <a target=xrefwindow id=d28749e2175 href="http://www.ncbi.nlm.nih.gov/pubmed/11877563">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2178 href="https://doi.org/10.1053/ajkd.2002.31388">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d28749e2187 class=n-a></a>Böhm M, Thoenes M, Danchin N, <i> et al.</i>: Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. <i>J Hypertens.</i> 2007; <b>25</b>(11): 2317–24. <a target=xrefwindow id=d28749e2198 href="http://www.ncbi.nlm.nih.gov/pubmed/17921828">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2201 href="https://doi.org/10.1097/HJH.0b013e3282ef1c5f">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d28749e2210 class=n-a></a>Redon J, Liao Y, Lozano JV, <i> et al.</i>: Ambulatory blood pressure and microalbuminuria in essential hypertension: role of circadian variability. <i>J Hypertens.</i> 1994; <b>12</b>(8): 947–53. <a target=xrefwindow id=d28749e2221 href="http://www.ncbi.nlm.nih.gov/pubmed/7814854">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2224 href="https://doi.org/10.1097/00004872-199408000-00013">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d28749e2234 class=n-a></a>Bianchi S, Bigazzi R, Baldari G, <i> et al.</i>: Diurnal variations of blood pressure and microalbuminuria in essential hypertension. <i>Am J Hypertens.</i> 1994; <b>7</b>(1): 23–9. <a target=xrefwindow id=d28749e2245 href="http://www.ncbi.nlm.nih.gov/pubmed/8136107">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2248 href="https://doi.org/10.1093/ajh/7.1.23">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d28749e2257 class=n-a></a>Hansen KW, Mau Pedersen M, Marshall SM, <i> et al.</i>: Circadian variation of blood pressure in patients with diabetic nephropathy. <i>Diabetologia.</i> 1992; <b>35</b>(11): 1074–9. <a target=xrefwindow id=d28749e2268 href="http://www.ncbi.nlm.nih.gov/pubmed/1473618">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2271 href="https://doi.org/10.1007/bf02221684">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d28749e2280 class=n-a></a>Ruiz-Hurtado G, Ruilope LM, de La Sierra A, <i> et al.</i>: Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. <i>Diabetes Care.</i> 2016; <b>39</b>(10): 1729–37. <a target=xrefwindow id=d28749e2291 href="http://www.ncbi.nlm.nih.gov/pubmed/27515965">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2294 href="https://doi.org/10.2337/dc16-0748">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d28749e2303 class=n-a></a>Fagard RH, Celis H, Thijs L, <i> et al.</i>: Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. <i>Hypertension.</i> 2008; <b>51</b>(1): 55–61. <a target=xrefwindow id=d28749e2314 href="http://www.ncbi.nlm.nih.gov/pubmed/18039980">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2317 href="https://doi.org/10.1161/HYPERTENSIONAHA.107.100727">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d28749e2326 class=n-a></a>Dolan E, Stanton A, Thijs L, <i> et al.</i>: Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. <i>Hypertension.</i> 2005; <b>46</b>(1): 156–61. <a target=xrefwindow id=d28749e2337 href="http://www.ncbi.nlm.nih.gov/pubmed/15939805">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2340 href="https://doi.org/10.1161/01.HYP.0000170138.56903.7a">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736511859"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e2349 class=n-a></a>Hata J, Fukuhara M, Sakata S, <i> et al.</i>: White-coat and masked hypertension are associated with albuminuria in a general population: the Hisayama Study. <i>Hypertens Res.</i> 2017; <b>40</b>(11): 937–43. <a target=xrefwindow id=d28749e2360 href="http://www.ncbi.nlm.nih.gov/pubmed/28878300">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2363 href="https://doi.org/10.1038/hr.2017.74">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736511859">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d28749e2377 class=n-a></a>Tomiyama M, Horio T, Yoshii M, <i> et al.</i>: Masked hypertension and target organ damage in treated hypertensive patients. <i>Am J Hypertens.</i> 2006; <b>19</b>(9): 880–6. <a target=xrefwindow id=d28749e2388 href="http://www.ncbi.nlm.nih.gov/pubmed/16942927">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2391 href="https://doi.org/10.1016/j.amjhyper.2006.03.006">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d28749e2400 class=n-a></a>Matsui Y, Eguchi K, Ishikawa J, <i> et al.</i>: Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement. <i>Am J Hypertens.</i> 2007; <b>20</b>(4): 385–91. <a target=xrefwindow id=d28749e2411 href="http://www.ncbi.nlm.nih.gov/pubmed/17386344">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2414 href="https://doi.org/10.1016/j.amjhyper.2006.10.008">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d28749e2423 class=n-a></a>Oliveras A, Armario P, Hernández-del Rey R, <i> et al.</i>: Urinary albumin excretion is associated with true resistant hypertension. <i>J Hum Hypertens.</i> 2010; <b>24</b>(1): 27–33. <a target=xrefwindow id=d28749e2434 href="http://www.ncbi.nlm.nih.gov/pubmed/19421225">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2437 href="https://doi.org/10.1038/jhh.2009.35">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d28749e2446 class=n-a></a>Williams B, Mancia G, Spiering W, <i> et al.</i>: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>J Hypertens.</i> 2018; <b>36</b>(10): 1953–2041. <a target=xrefwindow id=d28749e2457 href="http://www.ncbi.nlm.nih.gov/pubmed/30234752">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2460 href="https://doi.org/10.1097/HJH.0000000000001940">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d28749e2469 class=n-a></a>Leoncini G, Sacchi G, Ravera M, <i> et al.</i>: Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. <i>J Hum Hypertens.</i> 2002; <b>16</b>(6): 399–404. <a target=xrefwindow id=d28749e2480 href="http://www.ncbi.nlm.nih.gov/pubmed/12037694">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2483 href="https://doi.org/10.1038/sj.jhh.1001408">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d28749e2492 class=n-a></a>Pontremoli R, Ravera M, Bezante GP, <i> et al.</i>: Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. <i>J Hypertens.</i> 1999; <b>17</b>(7): 993–1000. <a target=xrefwindow id=d28749e2503 href="http://www.ncbi.nlm.nih.gov/pubmed/10419073">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2506 href="https://doi.org/10.1097/00004872-199917070-00016">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d28749e2516 class=n-a></a>Lieb W, Mayer B, Stritzke J, <i> et al.</i>: Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. <i>Nephrol Dial Transplant.</i> 2006; <b>21</b>(10): 2780–7. <a target=xrefwindow id=d28749e2527 href="http://www.ncbi.nlm.nih.gov/pubmed/16880179">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2530 href="https://doi.org/10.1093/ndt/gfl364">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d28749e2539 class=n-a></a>Tsioufis C, Stefanadis C, Toutouza M, <i> et al.</i>: Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects. <i>J Hum Hypertens.</i> 2002; <b>16</b>(4): 249–54. <a target=xrefwindow id=d28749e2550 href="http://www.ncbi.nlm.nih.gov/pubmed/11967718">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2553 href="https://doi.org/10.1038/sj.jhh.1001379">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d28749e2562 class=n-a></a>Bigazzi R, Bianchi S, Nenci R, <i> et al.</i>: Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. <i>J Hum Hypertens.</i> 1995; <b>9</b>(10): 827–33. <a target=xrefwindow id=d28749e2573 href="http://www.ncbi.nlm.nih.gov/pubmed/8576899">PubMed Abstract </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d28749e2582 class=n-a></a>Rodondi N, Yerly P, Gabriel A, <i> et al.</i>: Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults. <i>Nephrol Dial Transplant.</i> 2007; <b>22</b>(4): 1107–14. <a target=xrefwindow id=d28749e2593 href="http://www.ncbi.nlm.nih.gov/pubmed/17205961">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2596 href="https://doi.org/10.1093/ndt/gfl733">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d28749e2605 class=n-a></a>Geraci G, Mulè G, Costanza G, <i> et al.</i>: Relationship Between Carotid Atherosclerosis and Pulse Pressure with Renal Hemodynamics in Hypertensive Patients. <i>Am J Hypertens.</i> 2016; <b>29</b>(4): 519–27. <a target=xrefwindow id=d28749e2616 href="http://www.ncbi.nlm.nih.gov/pubmed/26232780">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2619 href="https://doi.org/10.1093/ajh/hpv130">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2623 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4886487">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d28749e2632 class=n-a></a>Jørgensen L, Jenssen T, Johnsen SH, <i> et al.</i>: Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromsø Study. <i>Eur Heart J.</i> 2007; <b>28</b>(3): 363–9. <a target=xrefwindow id=d28749e2643 href="http://www.ncbi.nlm.nih.gov/pubmed/17132646">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2646 href="https://doi.org/10.1093/eurheartj/ehl394">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d28749e2656 class=n-a></a>Cerasola G, Cottone S, Mulé G, <i> et al.</i>: Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. <i>J Hypertens.</i> 1996; <b>14</b>(7): 915–20. <a target=xrefwindow id=d28749e2667 href="http://www.ncbi.nlm.nih.gov/pubmed/8818932">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2670 href="https://doi.org/10.1097/00004872-199607000-00016">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d28749e2679 class=n-a></a>Newman DJ, Mattock MB, Dawnay AB, <i> et al.</i>: Systematic review on urine albumin testing for early detection of diabetic complications. <i>Health Technol Assess.</i> 2005; <b>9</b>(30): iii–vi, xiii–163. <a target=xrefwindow id=d28749e2690 href="http://www.ncbi.nlm.nih.gov/pubmed/16095545">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2693 href="https://doi.org/10.3310/hta9300">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d28749e2702 class=n-a></a>Jensen JS, Borch-Johnsen K, Feldt-Rasmussen B, <i> et al.</i>: Urinary albumin excretion and history of acute myocardial infarction in a cross-sectional population study of 2,613 individuals. <i>Eur J Cardiovasc Prev Rehabil.</i> 1997; <b>4</b>(2): 121–5. <a target=xrefwindow id=d28749e2713 href="http://www.ncbi.nlm.nih.gov/pubmed/9304493">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2716 href="https://doi.org/10.1177/174182679700400208">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d28749e2725 class=n-a></a>Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, <i> et al.</i>: Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. <i>Circulation.</i> 2004; <b>110</b>(1): 32–5. <a target=xrefwindow id=d28749e2736 href="http://www.ncbi.nlm.nih.gov/pubmed/15210602">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2739 href="https://doi.org/10.1161/01.CIR.0000133312.96477.48">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736511862"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e2748 class=n-a></a>Kumar Jha P, Ete T, Malviya A, <i> et al.</i>: Microalbuminuria: Correlation With Prevalence and Severity of Coronary Artery Disease in Non-Diabetics. <i>J Clin Med Res.</i> 2017; <b>9</b>(10): 838–43. <a target=xrefwindow id=d28749e2759 href="http://www.ncbi.nlm.nih.gov/pubmed/28912920">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2762 href="https://doi.org/10.14740/jocmr2785w">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2766 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5593431">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736511862">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727820042"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e2779 class=n-a></a>Swoboda PP, McDiarmid AK, Erhayiem B, <i> et al.</i>: Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. <i>J Am Heart Assoc.</i> 2017; <b>6</b>(7): pii: e005539. <a target=xrefwindow id=d28749e2790 href="http://www.ncbi.nlm.nih.gov/pubmed/28716801">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2793 href="https://doi.org/10.1161/JAHA.117.005539">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2797 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5586286">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727820042">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d28749e2811 class=n-a></a>Navaneethan SD, Schold JD, Arrigain S, <i> et al.</i>: Cause-Specific Deaths in Non-Dialysis-Dependent CKD. <i>J Am Soc Nephrol.</i> 2015; <b>26</b>(10): 2512–20. <a target=xrefwindow id=d28749e2822 href="http://www.ncbi.nlm.nih.gov/pubmed/26045089">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2825 href="https://doi.org/10.1681/ASN.2014101034">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2829 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4587705">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d28749e2838 class=n-a></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int (Suppl.).</i> 2013; <b>3</b>(1): 1–150. <a target=xrefwindow id=d28749e2846 href="https://www.sciencedirect.com/journal/kidney-international-supplements/vol/3/issue/1">Reference Source</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d28749e2855 class=n-a></a>Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. <i>Ann Intern Med.</i> 2013; <b>158</b>(11): 825–30. <a target=xrefwindow id=d28749e2863 href="http://www.ncbi.nlm.nih.gov/pubmed/23732715">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2866 href="https://doi.org/10.7326/0003-4819-158-11-201306040-00007">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d28749e2875 class=n-a></a>Ruggenenti P, Perna A, Mosconi L, <i> et al.</i>: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). <i>Kidney Int.</i> 1998; <b>53</b>(5): 1209–16. <a target=xrefwindow id=d28749e2886 href="http://www.ncbi.nlm.nih.gov/pubmed/9573535">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2889 href="https://doi.org/10.1046/j.1523-1755.1998.00874.x">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731116019"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e2898 class=n-a></a>Sumida K, Molnar MZ, Potukuchi PK, <i> et al.</i>: Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. <i>Clin J Am Soc Nephrol.</i> 2017; <b>12</b>(12): 1941–9. <a target=xrefwindow id=d28749e2909 href="http://www.ncbi.nlm.nih.gov/pubmed/28893924">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2912 href="https://doi.org/10.2215/CJN.02720317">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2916 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5718265">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731116019">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d28749e2929 class=n-a></a>de Boer IH, Gao X, Cleary PA, <i> et al.</i>: Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clin J Am Soc Nephrol.</i> 2016; <b>11</b>(11): 1969–77. <a target=xrefwindow id=d28749e2940 href="http://www.ncbi.nlm.nih.gov/pubmed/27797889">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2943 href="https://doi.org/10.2215/CJN.02870316">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2947 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5108190">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d28749e2957 class=n-a></a>Lambers Heerspink HJ, Gansevoort RT: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. <i>Clin J Am Soc Nephrol.</i> 2015; <b>10</b>(6): 1079–88. <a target=xrefwindow id=d28749e2965 href="http://www.ncbi.nlm.nih.gov/pubmed/25887073">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2968 href="https://doi.org/10.2215/CJN.11511114">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2971 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4455219">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d28749e2980 class=n-a></a>Heerspink HJ, Kröpelin TF, Hoekman J, <i> et al.</i>: Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. <i>J Am Soc Nephrol.</i> 2015; <b>26</b>(8): 2055–64. <a target=xrefwindow id=d28749e2991 href="http://www.ncbi.nlm.nih.gov/pubmed/25421558">PubMed Abstract </a> | <a target=xrefwindow id=d28749e2994 href="https://doi.org/10.1681/ASN.2014070688">Publisher Full Text </a> | <a target=xrefwindow id=d28749e2998 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4520175">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727086085"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3007 class=n-a></a>Carrero JJ, Grams ME, Sang Y, <i> et al.</i>: Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. <i>Kidney Int.</i> 2017; <b>91</b>(1): 244–51. <a target=xrefwindow id=d28749e3018 href="http://www.ncbi.nlm.nih.gov/pubmed/27927597">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3021 href="https://doi.org/10.1016/j.kint.2016.09.037">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3025 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5523054">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727086085">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d28749e3038 class=n-a></a>Schmieder RE, Mann JF, Schumacher H, <i> et al.</i>: Changes in albuminuria predict mortality and morbidity in patients with vascular disease. <i>J Am Soc Nephrol.</i> 2011; <b>22</b>(7): 1353–64. <a target=xrefwindow id=d28749e3049 href="http://www.ncbi.nlm.nih.gov/pubmed/21719791">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3052 href="https://doi.org/10.1681/ASN.2010091001">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3056 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3137583">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d28749e3065 class=n-a></a>Schmieder RE, Schutte R, Schumacher H, <i> et al.</i>: Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. <i>Diabetologia.</i> 2014; <b>57</b>(10): 2019–29. <a target=xrefwindow id=d28749e3076 href="http://www.ncbi.nlm.nih.gov/pubmed/25037746">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3079 href="https://doi.org/10.1007/s00125-014-3330-9">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733689460"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3088 class=n-a></a>Weiner DE, Park M, Tighiouart H, <i> et al.</i>: Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. <i>Am J Kidney Dis.</i> 2019; <b>73</b>(1): 51–61. <a target=xrefwindow id=d28749e3099 href="http://www.ncbi.nlm.nih.gov/pubmed/30037726">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3102 href="https://doi.org/10.1053/j.ajkd.2018.05.015">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3106 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6309643">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733689460">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d28749e3120 class=n-a></a>Mancia G, Fagard R, Narkiewicz K, <i> et al.</i>: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Eur Heart J.</i> 2013; <b>34</b>(28): 2159–219. <a target=xrefwindow id=d28749e3131 href="http://www.ncbi.nlm.nih.gov/pubmed/23771844">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3134 href="https://doi.org/10.1093/eurheartj/eht151">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d28749e3143 class=n-a></a>James PA, Oparil S, Carter BL, <i> et al.</i>: 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA.</i> 2014; <b>311</b>(5): 507–20. <a target=xrefwindow id=d28749e3154 href="http://www.ncbi.nlm.nih.gov/pubmed/24352797">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3157 href="https://doi.org/10.1001/jama.2013.284427">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5108956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3166 class=n-a></a>Appel LJ, Wright JT Jr, Greene T, <i> et al.</i>: Intensive blood-pressure control in hypertensive chronic kidney disease. <i>N Engl J Med.</i> 2010; <b>363</b>(10): 918–29. <a target=xrefwindow id=d28749e3177 href="http://www.ncbi.nlm.nih.gov/pubmed/20818902">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3180 href="https://doi.org/10.1056/NEJMoa0910975">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3184 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3662974">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5108956">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725924077"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3197 class=n-a></a>SPRINT Research Group, Wright JT Jr, Williamson JD, <i> et al.</i>: A Randomized Trial of Intensive versus Standard Blood-Pressure Control. <i>N Engl J Med.</i> 2015; <b>373</b>(22): 2103–16. <a target=xrefwindow id=d28749e3208 href="http://www.ncbi.nlm.nih.gov/pubmed/26551272">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3211 href="https://doi.org/10.1056/NEJMoa1511939">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3215 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4689591">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725924077">F1000 Recommendation</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730774395"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3228 class=n-a></a>Malhotra R, Nguyen HA, Benavente O, <i> et al.</i>: Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. <i>JAMA Intern Med.</i> 2017; <b>177</b>(10): 1498–505. <a target=xrefwindow id=d28749e3239 href="http://www.ncbi.nlm.nih.gov/pubmed/28873137">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3242 href="https://doi.org/10.1001/jamainternmed.2017.4377">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3246 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5704908">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730774395">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d28749e3259 class=n-a></a>Kovesdy CP, Alrifai A, Gosmanova EO, <i> et al.</i>: Age and Outcomes Associated with BP in Patients with Incident CKD. <i>Clin J Am Soc Nephrol.</i> 2016; <b>11</b>(5): 821–31. <a target=xrefwindow id=d28749e3270 href="http://www.ncbi.nlm.nih.gov/pubmed/27103623">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3273 href="https://doi.org/10.2215/CJN.08660815">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3277 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4858482">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d28749e3287 class=n-a></a>Weiss JW, Peters D, Yang X, <i> et al.</i>: Systolic BP and Mortality in Older Adults with CKD. <i>Clin J Am Soc Nephrol.</i> 2015; <b>10</b>(9): 1553–9. <a target=xrefwindow id=d28749e3298 href="http://www.ncbi.nlm.nih.gov/pubmed/26276142">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3301 href="https://doi.org/10.2215/CJN.11391114">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3305 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4559521">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726365265"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3314 class=n-a></a>Williamson JD, Supiano MA, Applegate WB, <i> et al.</i>: Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. <i>JAMA.</i> 2016; <b>315</b>(24): 2673–82. <a target=xrefwindow id=d28749e3325 href="http://www.ncbi.nlm.nih.gov/pubmed/27195814">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3328 href="https://doi.org/10.1001/jama.2016.7050">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3332 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4988796">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726365265">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2638966"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3345 class=n-a></a>ACCORD Study Group, Cushman WC, Evans GW, <i> et al.</i>: Effects of intensive blood-pressure control in type 2 diabetes mellitus. <i>N Engl J Med.</i> 2010; <b>362</b>(17): 1575–85. <a target=xrefwindow id=d28749e3356 href="http://www.ncbi.nlm.nih.gov/pubmed/20228401">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3359 href="https://doi.org/10.1056/NEJMoa1001286">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3363 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4123215">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2638966">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732125262"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3376 class=n-a></a>Reboussin DM, Allen NB, Griswold ME, <i> et al.</i>: Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol.</i> 2018; <b>71</b>(19): 2176–98. <a target=xrefwindow id=d28749e3387 href="https://doi.org/10.1016/j.jacc.2017.11.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732125262">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734849477"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3400 class=n-a></a>Coresh J, Heerspink HJL, Sang Y, <i> et al.</i>: Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. <i>Lancet Diabetes Endocrinol.</i> 2019; <b>7</b>(2): 115–27. <a target=xrefwindow id=d28749e3411 href="http://www.ncbi.nlm.nih.gov/pubmed/30635225">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3414 href="https://doi.org/10.1016/S2213-8587(18)30313-9">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3418 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6379893">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734849477">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734849476"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3431 class=n-a></a>Heerspink HJL, Greene T, Tighiouart H, <i> et al.</i>: Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes Endocrinol.</i> 2019; <b>7</b>(2): 128–39. <a target=xrefwindow id=d28749e3442 href="http://www.ncbi.nlm.nih.gov/pubmed/30635226">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3445 href="https://doi.org/10.1016/S2213-8587(18)30314-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734849476">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d28749e3459 class=n-a></a>Ruiz-Hurtado G, Sarafidis P, Fernández-Alfonso MS, <i> et al.</i>: Global cardiovascular protection in chronic kidney disease. <i>Nat Rev Cardiol.</i> 2016; <b>13</b>(10): 603–8. <a target=xrefwindow id=d28749e3470 href="http://www.ncbi.nlm.nih.gov/pubmed/27053454">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3473 href="https://doi.org/10.1038/nrcardio.2016.48">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d28749e3482 class=n-a></a>Viazzi F, Muiesan ML, Schillaci G, <i> et al.</i>: Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis. <i>J Hypertens.</i> 2016; <b>34</b>(9): 1689–97. <a target=xrefwindow id=d28749e3493 href="http://www.ncbi.nlm.nih.gov/pubmed/27254313">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3496 href="https://doi.org/10.1097/HJH.0000000000000991">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d28749e3505 class=n-a></a>Brenner BM, Cooper ME, de Zeeuw D, <i> et al.</i>: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>N Engl J Med.</i> 2001; <b>345</b>(12): 861–9. <a target=xrefwindow id=d28749e3516 href="http://www.ncbi.nlm.nih.gov/pubmed/11565518">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3519 href="https://doi.org/10.1056/NEJMoa011161">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d28749e3528 class=n-a></a>Lewis EJ, Hunsicker LG, Clarke WR, <i> et al.</i>: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. <i>N Engl J Med.</i> 2001; <b>345</b>(12): 851–60. <a target=xrefwindow id=d28749e3539 href="http://www.ncbi.nlm.nih.gov/pubmed/11565517">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3542 href="https://doi.org/10.1056/NEJMoa011303">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d28749e3551 class=n-a></a>de Galan BE, Perkovic V, Ninomiya T, <i> et al.</i>: Lowering blood pressure reduces renal events in type 2 diabetes. <i>J Am Soc Nephrol.</i> 2009; <b>20</b>(4): 883–92. <a target=xrefwindow id=d28749e3562 href="http://www.ncbi.nlm.nih.gov/pubmed/19225038">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3565 href="https://doi.org/10.1681/ASN.2008070667">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3569 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2663832">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9271956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3578 class=n-a></a>Haller H, Ito S, Izzo JL Jr, <i> et al.</i>: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. <i>N Engl J Med.</i> 2011; <b>364</b>(10): 907–17. <a target=xrefwindow id=d28749e3589 href="http://www.ncbi.nlm.nih.gov/pubmed/21388309">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3592 href="https://doi.org/10.1056/NEJMoa1007994">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9271956">F1000 Recommendation</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1104759"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3606 class=n-a></a>ONTARGET Investigators, Yusuf S, Teo KK, <i> et al.</i>: Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med.</i> 2008; <b>358</b>(15): 1547–59. <a target=xrefwindow id=d28749e3617 href="http://www.ncbi.nlm.nih.gov/pubmed/18378520">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3620 href="https://doi.org/10.1056/NEJMoa0801317">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1104759">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718171017"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3633 class=n-a></a>Fried LF, Emanuele N, Zhang JH, <i> et al.</i>: Combined angiotensin inhibition for the treatment of diabetic nephropathy. <i>N Engl J Med.</i> 2013; <b>369</b>(20): 1892–903. <a target=xrefwindow id=d28749e3644 href="http://www.ncbi.nlm.nih.gov/pubmed/24206457">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3647 href="https://doi.org/10.1056/NEJMoa1303154">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718171017">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717962604"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3660 class=n-a></a>Parving HH, Brenner BM, McMurray JJ, <i> et al.</i>: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. <i>N Engl J Med.</i> 2012; <b>367</b>(23): 2204–13. <a target=xrefwindow id=d28749e3671 href="http://www.ncbi.nlm.nih.gov/pubmed/23121378">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3674 href="https://doi.org/10.1056/NEJMoa1208799">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717962604">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1448963"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3687 class=n-a></a>Mehdi UF, Adams-Huet B, Raskin P, <i> et al.</i>: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. <i>J Am Soc Nephrol.</i> 2009; <b>20</b>(12): 2641–50. <a target=xrefwindow id=d28749e3698 href="http://www.ncbi.nlm.nih.gov/pubmed/19926893">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3701 href="https://doi.org/10.1681/ASN.2009070737">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3705 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2794224">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1448963">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d28749e3718 class=n-a></a>Márquez DF, Ruiz-Hurtado G, Ruilope LM, <i> et al.</i>: An update of the blockade of the renin angiotensin aldosterone system in clinical practice. <i>Expert Opin Pharmacother.</i> 2015; <b>16</b>(15): 2283–92. <a target=xrefwindow id=d28749e3729 href="http://www.ncbi.nlm.nih.gov/pubmed/26389772">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3732 href="https://doi.org/10.1517/14656566.2015.1079623">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d28749e3741 class=n-a></a>Marquez DF, Ruiz-Hurtado G, Ruilope L: The impact of antihypertensives on kidney disease [version 1; peer review: 2 approved]. <i>F1000Res.</i> 2017; <b>6</b>: 611. <a target=xrefwindow id=d28749e3749 href="http://www.ncbi.nlm.nih.gov/pubmed/28529721">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3752 href="https://doi.org/10.12688/f1000research.9916.1">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3755 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5414822">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718308285"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3765 class=n-a></a>Kolkhof P, Delbeck M, Kretschmer A, <i> et al.</i>: Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. <i>J Cardiovasc Pharmacol.</i> 2014; <b>64</b>(1): 69–78. <a target=xrefwindow id=d28749e3776 href="http://www.ncbi.nlm.nih.gov/pubmed/24621652">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3779 href="https://doi.org/10.1097/FJC.0000000000000091">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718308285">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718013671"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3792 class=n-a></a>Pitt B, Kober L, Ponikowski P, <i> et al.</i>: Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>Eur Heart J.</i> 2013; <b>34</b>(31): 2453–63. <a target=xrefwindow id=d28749e3803 href="http://www.ncbi.nlm.nih.gov/pubmed/23713082">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3806 href="https://doi.org/10.1093/eurheartj/eht187">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3810 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3743070">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718013671">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725760259"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3823 class=n-a></a>Bakris GL, Agarwal R, Chan JC, <i> et al.</i>: Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. <i>JAMA.</i> 2015; <b>314</b>(9): 884–94. <a target=xrefwindow id=d28749e3834 href="http://www.ncbi.nlm.nih.gov/pubmed/26325557">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3837 href="https://doi.org/10.1001/jama.2015.10081">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725760259">F1000 Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725243592"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3850 class=n-a></a>Weir MR, Bakris GL, Bushinsky DA, <i> et al.</i>: Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. <i>N Engl J Med.</i> 2015; <b>372</b>(3): 211–21. <a target=xrefwindow id=d28749e3861 href="http://www.ncbi.nlm.nih.gov/pubmed/25415805">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3864 href="https://doi.org/10.1056/NEJMoa1410853">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725243592">F1000 Recommendation</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725243590"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3877 class=n-a></a>Packham DK, Rasmussen HS, Lavin PT, <i> et al.</i>: Sodium zirconium cyclosilicate in hyperkalemia. <i>N Engl J Med.</i> 2015; <b>372</b>(3): 222–31. <a target=xrefwindow id=d28749e3888 href="http://www.ncbi.nlm.nih.gov/pubmed/25415807">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3891 href="https://doi.org/10.1056/NEJMoa1411487">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725243590">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727241641"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3904 class=n-a></a>Meaney CJ, Beccari MV, Yang Y, <i> et al.</i>: Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia. <i>Pharmacotherapy.</i> 2017; <b>37</b>(4): 401–11. <a target=xrefwindow id=d28749e3915 href="http://www.ncbi.nlm.nih.gov/pubmed/28122118">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3918 href="https://doi.org/10.1002/phar.1906">Publisher Full Text </a> | <a target=xrefwindow id=d28749e3922 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5388568">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727241641">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725794423"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3936 class=n-a></a>Zinman B, Wanner C, Lachin JM, <i> et al.</i>: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>N Engl J Med.</i> 2015; <b>373</b>(22): 2117–28. <a target=xrefwindow id=d28749e3947 href="http://www.ncbi.nlm.nih.gov/pubmed/26378978">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3950 href="https://doi.org/10.1056/NEJMoa1504720">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725794423">F1000 Recommendation</a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726421733"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3963 class=n-a></a>Wanner C, Inzucchi SE, Lachin JM, <i> et al.</i>: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>N Engl J Med.</i> 2016; <b>375</b>(4): 323–34. <a target=xrefwindow id=d28749e3974 href="http://www.ncbi.nlm.nih.gov/pubmed/27299675">PubMed Abstract </a> | <a target=xrefwindow id=d28749e3977 href="https://doi.org/10.1056/NEJMoa1515920">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726421733">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727709200"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e3990 class=n-a></a>Neal B, Perkovic V, Mahaffey KW, <i> et al.</i>: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>N Engl J Med.</i> 2017; <b>377</b>(7): 644–57. <a target=xrefwindow id=d28749e4001 href="http://www.ncbi.nlm.nih.gov/pubmed/28605608">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4004 href="https://doi.org/10.1056/NEJMoa1611925">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727709200">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735545347"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4017 class=n-a></a>Perkovic V, Jardine MJ, Neal B, <i> et al.</i>: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>N Engl J Med.</i> 2019; <b>380</b>(24): 2295–306. <a target=xrefwindow id=d28749e4028 href="http://www.ncbi.nlm.nih.gov/pubmed/30990260">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4031 href="https://doi.org/10.1056/NEJMoa1811744">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735545347">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726419704"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4044 class=n-a></a>Marso SP, Daniels GH, Brown-Frandsen K, <i> et al.</i>: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2016; <b>375</b>(4): 311–22. <a target=xrefwindow id=d28749e4055 href="http://www.ncbi.nlm.nih.gov/pubmed/27295427">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4058 href="https://doi.org/10.1056/NEJMoa1603827">Publisher Full Text </a> | <a target=xrefwindow id=d28749e4062 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4985288">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726419704">F1000 Recommendation</a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726744841"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4075 class=n-a></a>Marso SP, Bain SC, Consoli A, <i> et al.</i>: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>N Engl J Med.</i> 2016; <b>375</b>(19): 1834–44. <a target=xrefwindow id=d28749e4086 href="http://www.ncbi.nlm.nih.gov/pubmed/27633186">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4089 href="https://doi.org/10.1056/NEJMoa1607141">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726744841">F1000 Recommendation</a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730126538"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4103 class=n-a></a>Mann JFE, Ørsted DD, Brown-Frandsen K, <i> et al.</i>: Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2017; <b>377</b>(9): 839–48. <a target=xrefwindow id=d28749e4114 href="http://www.ncbi.nlm.nih.gov/pubmed/28854085">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4117 href="https://doi.org/10.1056/NEJMoa1616011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730126538">F1000 Recommendation</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d28749e4130 class=n-a></a>Mann JFE, Green D, Jamerson K, <i> et al.</i>: Avosentan for overt diabetic nephropathy. <i>J Am Soc Nephrol.</i> 2010; <b>21</b>(3): 527–35. <a target=xrefwindow id=d28749e4141 href="http://www.ncbi.nlm.nih.gov/pubmed/20167702">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4144 href="https://doi.org/10.1681/ASN.2009060593">Publisher Full Text </a> | <a target=xrefwindow id=d28749e4148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2831858">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9958957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4157 class=n-a></a>Kohan DE, Pritchett Y, Molitch M, <i> et al.</i>: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. <i>J Am Soc Nephrol.</i> 2011; <b>22</b>(4): 763–72. <a target=xrefwindow id=d28749e4168 href="http://www.ncbi.nlm.nih.gov/pubmed/21372210">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4171 href="https://doi.org/10.1681/ASN.2010080869">Publisher Full Text </a> | <a target=xrefwindow id=d28749e4175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3065231">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9958957">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718346572"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4188 class=n-a></a>de Zeeuw D, Coll B, Andress D, <i> et al.</i>: The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. <i>J Am Soc Nephrol.</i> 2014; <b>25</b>(5): 1083–93. <a target=xrefwindow id=d28749e4199 href="http://www.ncbi.nlm.nih.gov/pubmed/24722445">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4202 href="https://doi.org/10.1681/ASN.2013080830">Publisher Full Text </a> | <a target=xrefwindow id=d28749e4206 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4005314">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718346572">F1000 Recommendation</a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735578274"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4219 class=n-a></a>Heerspink HJL, Parving HH, Andress DL, <i> et al.</i>: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet.</i> 2019; <b>393</b>(10184): 1937–47. <a target=xrefwindow id=d28749e4230 href="http://www.ncbi.nlm.nih.gov/pubmed/30995972">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4233 href="https://doi.org/10.1016/S0140-6736(19)30772-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735578274">F1000 Recommendation</a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d28749e4246 class=n-a></a>Douglas K, O'Malley PG, Jackson JL: Meta-analysis: the effect of statins on albuminuria. <i>Ann Intern Med.</i> 2006; <b>145</b>(2): 117–24. <a target=xrefwindow id=d28749e4254 href="http://www.ncbi.nlm.nih.gov/pubmed/16847294">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4257 href="https://doi.org/10.7326/0003-4819-145-2-200607180-00009">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725533550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4267 class=n-a></a>Athyros VG, Katsiki N, Karagiannis A, <i> et al.</i>: Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? <i>Expert Opin Pharmacother.</i> 2015; <b>16</b>(10): 1449–61. <a target=xrefwindow id=d28749e4278 href="http://www.ncbi.nlm.nih.gov/pubmed/26037614">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4281 href="https://doi.org/10.1517/14656566.2015.1053464">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725533550">F1000 Recommendation</a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d28749e4294 class=n-a></a>Zhang Z, Wu P, Zhang J, <i> et al.</i>: The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. <i>Pharmacol Res.</i> 2016; <b>105</b>: 74–83. <a target=xrefwindow id=d28749e4305 href="http://www.ncbi.nlm.nih.gov/pubmed/26776964">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4308 href="https://doi.org/10.1016/j.phrs.2016.01.005">Publisher Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717962487"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28749e4317 class=n-a></a>Jun M, Zhu B, Tonelli M, <i> et al.</i>: Effects of fibrates in kidney disease: a systematic review and meta-analysis. <i>J Am Coll Cardiol.</i> 2012; <b>60</b>(20): 2061–71. <a target=xrefwindow id=d28749e4328 href="http://www.ncbi.nlm.nih.gov/pubmed/23083786">PubMed Abstract </a> | <a target=xrefwindow id=d28749e4331 href="https://doi.org/10.1016/j.jacc.2012.07.049">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717962487">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 19 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1659.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1659.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Unidad de Hipertensi&oacute;n Arterial-Servicio de Cl&iacute;nica M&eacute;dica, Hospital San Bernardo, Salta, Argentina<br/> <sup>2</sup> Instituto de Investigaci&oacute;n Imas12 and Unidad de Hipertensi&oacute;n, Hospital 12 de Octubre, Madrid, Spain<br/> <sup>3</sup> Departamento de Medicina Preventiva y Salud P&uacute;blica, Universidad Aut&oacute;noma, Madrid, Spain<br/> <sup>4</sup> Escuela de Estudios Postdoctorales and Investigaci&oacute;n, Universidad de Europa de Madrid, Madrid, Spain<br/> <p> <div class=margin-bottom> Diego Francisco M&aacute;rquez <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Gema Ruiz-Hurtado <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Julian Segura <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Luis Ruilope <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1659/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 19 Sep 2019, 8:1659 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.17212.1">https://doi.org/10.12688/f1000research.17212.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Márquez DF <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=18821 data-id=17212 data-downloads="" data-views="" data-scholar="10.12688/f1000research.17212.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1659/v1/pdf?article_uuid=7ec44b77-95d3-46b8-95c8-70e3099647c2" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.17212.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Márquez DF, Ruiz-Hurtado G, Segura J and Ruilope L. Microalbuminuria and cardiorenal risk: old and new evidence in different populations [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1659 (<a href="https://doi.org/10.12688/f1000research.17212.1" target=_blank>https://doi.org/10.12688/f1000research.17212.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=17212 id=mobile-track-article-signin-17212 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/17212?target=/articles/8-1659.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=18821 /> <input name=articleId type=hidden value=17212 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Peter Rossing</strong>, Steno Diabetes Center Copenhagen, Denmark; University of Copenhagen, Denmark </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Peter Rossing has received honoraria to his institution from services for AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, MSD, and Eli Lilly. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Chi-yuan Hsu</strong>, Division of Nephrology, University of California, San Francisco, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 19 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1659.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1659.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=56274-53131></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=49701-47436></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1659/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>19 Sep 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Peter Rossing</strong>, Steno Diabetes Center Copenhagen, Denmark; University of Copenhagen, Denmark </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Peter Rossing has received honoraria to his institution from services for AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, MSD, and Eli Lilly. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Chi-yuan Hsu</strong>, Division of Nephrology, University of California, San Francisco, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1659.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1659/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Microalbuminuria and cardiorenal risk: old...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1659/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1659/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1659/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Márquez DF et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1659/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1659",
            templates : {
                twitter : "Microalbuminuria and cardiorenal risk: old and new evidence in.... Márquez DF et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1659/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Microalbuminuria and cardiorenal risk: old and new evidence in different populations", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Microalbuminuria and cardiorenal risk: old and new evidence in different populations", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/17212/18821")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "18821");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "53131": 1,
                           "47435": 0,
                           "47436": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "ce2090bc-a4c7-41f7-855e-cb223a0ef697";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1659.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1659.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1659.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1659.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1659.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>